Article
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
All News
Article
The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.
Eric Dein
Tweet
#ACR21 Ab#1029 - Great poster by Dr. Guttmann, IRAD in Summit NJ:
▶️2019 EULAR/ACR SLE criteria vs to 1997 ACR & SLICC
⭐️64% SLE pts: all 3 criteria. 10% only SLICC, 3% '97 ACR, 2% EULAR/ACR
⭐️Simliar gender, racial disparities to prior criteria
@Rheumnow https://t.co/QzG78HJgw5 https://t.co/eyuYhj4Acf
Eric Dein
Tweet
#ACR21 Abst#1029 @Rheumnow https://t.co/QzG78HJgw5
What is your preferred SLE classification criteria?
Eric Dein
Tweet
#ACR21 Abs:#1429: ALPN-303: Dual BAFF/APRIL antagonist for SLE:
⭐️Encouraging immunomodulatory activity and efficacy in animal models. ⬇️ Plasma cells and Ig secretions in vitro & vivo
⭐️Well-tolerated in animals w/o adverse events
🔥Phase 1 study in healthy volunteers!
@Rheumnow
Md Yuzaiful Md Yusof
Tweet
#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC:
⬇️Titres of Abs in SLE vs controls
💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA
📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9
Md Yuzaiful Md Yusof
Tweet
📢#ACR21 #Abstr1421 Is #COVID19 vaccine safe and effective in #lupus? YES!! VOCOLUP study (N=1189 pts) showed:
💠~45% had a side-effect; of which 80% mild/moderate
💠Only 3% flared post💉(MSK + Fatigue); 10 required hospitalisation @RheumNow #ACRBest https://t.co/WF4aAfiX70 https://t.co/jc0HQoJymo
Mrinalini Dey
Tweet
Young patients with #SLE #lupus have a #multimorbidity burden similar to individuals 30years older than them.
A high #comorbidity burden is present in SLE pts of all ages compared to non-SLE.
How can we address this?
Abs#1049 #ACR21 #ACRBest @RheumNow
https://t.co/U6t8YBFUZz https://t.co/v7Fwof1gZc
Dr. John Cush
Tweet
Watch: Lupus Updates: Dr. Michelle Petri
Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting.
https://t.co/L7T2mNJVH0 https://t.co/MCQ7nJjCIY
Pedro Castillo
Tweet
Stopping/reducing hydroxychloroquine (HCQ) in SLE associated with increased flares, especially for those in low disease activity or in remission. Super helpful data to share with pts wanting to reduce/dc HCQ.
#ACR21 Abst#0959 Plenary Session II @RheumNow https://t.co/i7jPDN2sgZ
sheila
Tweet
Dr FCardwell et al on Health Info use in SLE pts b4 and during COVID19 using an online survey
🦋#lupus specialists & fam physicians - ⬆preferred & trusted health info sources but access to them ⬇frequent during covid19
A call to action?📢
@RheumNow #ACR21 abs0880 @rheumarhyme https://t.co/1NBEAlFvHx
Pedro Castillo
Tweet
Dr. Petri on COVID19 infection vs vaccination on SLE activity:
💠Infection = NO increase SLE activity
💠Infection =⬇️ cutaneous activity
💠Infection = ⬆️anti-cardiolipin IgG/M
💠Vaccination: no increase in activity NOR aCL IgG/M
https://t.co/fWbotSLS3o
#ACR21 Abst#0858 @RheumNow
Md Yuzaiful Md Yusof
Tweet
#ACR21 #Abstr0988 Can we predict who would develop #lupus? Data from the Nurses Health Study showed the best model by combining Genetic Risk Score + Clinical & lifestyle factors (AUC:0.72). Need more diversity as most pts were White and aged 50s @RheumNow https://t.co/4KHiZbRgUK https://t.co/QV4npith9H
Janet Pope
Tweet
How concerned should we be for #hydroxychloroquine retinopathy. >4000 pts prospectively followed. 1/2 w RA & 15% w #SLE. New risks Asian with pericentral pattern and overall. Length of time on use and ⬆️wt based dose per day & CKD all risks. Abst#0989 #ACR21 #ACRBest @RheumNow https://t.co/XTfdQpVC7H
Md Yuzaiful Md Yusof
Tweet
#ACR21 #Abstr0865 It’s time for T2T to achieve LLDAS in #lupus. In a study of N=2040 pts, mortality was 2.3% mainly due to infection. Remission off steroid was the best but only met in 14%. LLDAS-50 achieved in 48% pts and ⬇️mortality by 56% @RheumNow https://t.co/CddqMuFIOM https://t.co/g346Cbybep
Md Yuzaiful Md Yusof
Tweet
#ACR21 #Abstr0864 How does obesity (BMI=/>30) affect #lupus outcomes? Data from Toronto showed:
💠⬆️hs-CRP
💠No in disease activity over 3yrs
💠⬆️CV events (combination of low grade inflammation + hypertension)
@RheumNow https://t.co/IBu8uNSAJi https://t.co/2aqz5e3rwi
David Liew
Tweet
Can patient with low dx activity SLE stop HCQ, or at least try and reduce the dose?
Not if you want to avoid flares.
If there are safer subgroups to try it in, we haven't found them yet
(in fact higher dx activity➡️less risk ?other Rx)
SLICC inception #ACR21 ABST0959 @RheumNow https://t.co/NS2V4dEGHv
TheDaoIndex
Tweet
Keep the Hydroxychloroquine!
SLICC cohort eval flare risk in 1460 pts who⬇️or d/c HCQ:
👉pts in remission who d/c HCQ flared HR 2.77 (1.46,5.26)
👉pts in remission who⬇️dose flared HR 2.14 (1.34, 3.42)
Abst#0959 #Plenary #ACR21 @rheumnow #ACRbest https://t.co/92U215s8IP
TheDaoIndex
Tweet
Do you order EKGs in everyone starting HCQ? Do you avoid HCQ in patients with heart failure? Will these abstracts impact your practice? Click on link to read more....#ACR21 @rheumnow #HCQ https://t.co/fvUZAvNWa8
Md Yuzaiful Md Yusof
Tweet
#ACR21 #Abstr0858 Petri reported effect of #COVID and vaccination in #lupus cohort
💠No increase in activity post-infection
💠⬇️cutaneous activity
💠⬆️ aCL IgG and IgM post-infection,
💠No increase in SLE activity or aCL abs post-vaccination
@RheumNow https://t.co/iAaIfzf33c https://t.co/hA6sk6icrs
